biostudies-literatureEdelman MJNCI NIH HHS189-94https://www.ebi.ac.uk/biostudies/studies/S-EPMC4890680biostudies-literatureUnknown33(2)<h4>Purpose</h4>Overexpression of COX-2 correlates with advanced stage and worse outcomes in non-small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2). Exploratory analyses of studies that used COX-2 inhibitors have demonstrated potentially superior outcome in patients in whom the urinary metabolite of PGE2 (PGE-M) is suppressed. We hypothesized that patients with disease defined by PGE-M suppression would benefit from the addition of apricoxib to second-line docetaxel or pemetrexed.<h4>Patients and methods</h4>Patients with NSCLC who had disease progression after one line of platinum-based therapy, performance status of 0 to 2, and normal organ function were potentially eligible. Only patients with a ≥ 50% decrease in urinary PGJournal of clinical oncology : official journal of the American Society of Clinical OncologyRandomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.PMC4890680P30 CA134274Edelman MJSchneider BJTan MTOtterson GRogers JSFidler MJSanborn RESequist LVYang YFeliciano JKeresztes REvans TLMedeiros MZaknoen SLde Mayolo JAfalseRandomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.<h4>Purpose</h4>Overexpression of COX-2 correlates with advanced stage and worse outcomes in non-small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2-dependent prostaglandin E2 (PGE2). Exploratory analyses of studies that used COX-2 inhibitors have demonstrated potentially superior outcome in patients in whom the urinary metabolite of PGE2 (PGE-M) is suppressed. We hypothesized that patients with disease defined by PGE-M suppression would benefit from the addition of apricoxib to second-line docetaxel or pemetrexed.<h4>Patients and methods</h4>Patients with NSCLC who had disease progression after one line of platinum-based therapy, performance status of 0 to 2, and normal organ function were potentially eligible. Only patients with a ≥ 50% decrease in urinary PG2015-01-01T00:00:00Z2015 Jan2026-05-30T00:37:21.828Z2019-03-27T02:15:08ZS-EPMC48906802545244610.1200/JCO.2014.55.578910.1200/jco.2014.55.5789